Officials in British Columbia announced on Monday that patients currently taking reference biologics for rheumatological diseases and diabetes will be switched to biosimilar products within 6 months.
Officials in British Columbia announced on Monday that patients currently taking reference biologics for rheumatological diseases and diabetes will be switched to biosimilar products within 6 months.
The new policy will affect the approximately 20,400 British Columbians who have diabetes, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. Patients will have 6 months to work with their healthcare providers to transition to a biosimilar from their current reference product, and after November 25, 2019, PharmaCare, the publicly funded national drug coverage program, will no longer provide coverage for reference products other than in exceptional cases (such as when physicians deem individual patients medically unable to transition).
Patients who currently receive reference etanercept (Enbrel) will transition to Samsung Bioepis’ Brenzys (which is also approved in the United States as Eticovo) or Sandoz’s Erelzi. Those taking reference infliximab (Remicade) will be transitioned to Celltrion’s Inflectra or Samsung Bioepis’ and Merck’s Renflexis. Those who currently receive reference insulin glargine (Lantus) will be transitioned to Boehringer Ingelheim and Eli Lilly’s Basaglar.
Officials said that, as an immediate effect of the move toward lower-cost biosimilars, the province was able to make available 2 high-cost innovator drugs: the diabetes therapy empagliflozin (Jardiance) and the psoriatic arthritis drug ixekizumab (Taltz). Access to other products, such as rituximab and certolizumab, will also be expanded on the strength of the $96.6 million (approximately US $71.6 million) over the first 3 years of the program.
In the coming months, officials noted, the approximately 2700 patients receiving biologic treatment for inflammatory bowel disease will also transition their treatment to biosimilars, and more details of this switch will be made available shortly.
In a statement, Biosimilars Canada, a trade group representing biosimilar developers, applauded British Columbia on its decision. “Biosimilar medicines have an important role in supporting health care sustainability and patient care, and Biosimilars Canada congratulates the Government of British Columbia for its Canadian and North American leadership in promoting and expanding the use of biosimilar medicines,” said Michel Robidoux, chair of Biosimilars Canada and president and general manager of Sandoz Canada.
“Switching or transitioning patients from original biologic treatments to their corresponding biosimilar medicines is the responsible choice for those who manage drug budgets, and will help to ensure patient access to essential treatments for years to come,” added Jim Keon, president of Biosimilars Canada.
Biosimilar developer Merck also weighed in; in a statement, Anna Van Acker, president and managing director of Merck Canada Inc, said, “With this announcement, the government of British Columbia has reinforced the important role biosimilars can play in our healthcare system in helping broaden access not only to biologics, but also to innovative medicines overall.”
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.